


Mitochondria as Pharmacological Targets in Down syndrome

Daniela Valenti, Nady Braidy, Domenico De Rasmio, Anna Signorile, Leonardo Rossi, Atanas Georgiev Atanasov, Mariateresa Volpicella, Alexandra Henrion-Caude, Seyed Mohammad Nabavi, Rosa Anna Vacca



PII: S0891-5849(17)30730-X
DOI: <http://dx.doi.org/10.1016/j.freeradbiomed.2017.08.014>
Reference: FRB13424

To appear in: *Free Radical Biology and Medicine*

Received date: 28 June 2017
Revised date: 16 August 2017
Accepted date: 18 August 2017

Cite this article as: Daniela Valenti, Nady Braidy, Domenico De Rasmio, Anna Signorile, Leonardo Rossi, Atanas Georgiev Atanasov, Mariateresa Volpicella, Alexandra Henrion-Caude, Seyed Mohammad Nabavi and Rosa Anna Vacca, Mitochondria as Pharmacological Targets in Down syndrome, *Free Radical Biology and Medicine*, <http://dx.doi.org/10.1016/j.freeradbiomed.2017.08.014>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Mitochondria as Pharmacological Targets in Down syndrome

Daniela Valenti¹, Nady Braidy², Domenico De Rasmo¹, Anna Signorile³, Leonardo Rossi⁴, Atanas Georgiev Atanasov^{5,9,10}, Mariateresa Volpicella⁶, Alexandra Henrion-Caude⁷, Seyed Mohammad Nabavi⁸, Rosa Anna Vacca^{*1}

¹*Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies, National Council of Research, Bari, Italy;*

²*Centre for Healthy Brain Ageing, School of Psychiatry, University of New South Wales, Australia;*

³*Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari, Italy;*

⁴*Department of Clinical and Experimental Medicine, University of Pisa, Italy;*

⁵*Institute of Genetics and Animal Breeding of the Polish Academy of Sciences, 05-552 Jastrzebiec, Poland;*

⁶*Department of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari, Bari, Italy;*

⁷*INSERM U1163, Université Paris Descartes, Sorbonne Paris Cité, Institut Imagine, GenAtlas Platform, 24 Boulevard du Montparnasse, 75015 Paris, France;*

⁸*Applied Biotechnology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran;*

⁹*Department of Pharmacognosy, University of Vienna, 1090 Vienna, Austria;*

¹⁰*Department of Vascular Biology and Thrombosis Research, Center for Physiology and Pharmacology, Medical University of Vienna, 1090 Vienna, Austria.*

***Correspondence at:**

Rosa Anna Vacca, Institute of Biomembranes, Bioenergetics and Molecular Biothechnology, IBIOM - CNR, Via Amendola 165/A, 70126 Bari, Italy; Fax: +39 80 5443317; e-mail addresses: r.vacca@ibiom.cnr.it

Abbreviations

AD, Alzheimer's disease; AGO, Argonaute proteins; AMPK, AMP-activated protein kinase; ANTs, adenine nucleotide translocators; AK, adenylate kinase; APP, amyloid- β precursor protein; ASD, autism spectrum disorder; CAT, catalase; CNS, central nervous system; CoQ10, coenzyme Q10; Drp1, dynamin-related protein 1; DS, Down syndrome; DSCR, Down syndrome critical region; DYRK1A, dual-specificity tyrosine (Y)-phosphorylation regulated kinase 1A; EGCG, epigallocatechin-3 gallate; ERRs, estrogen-related receptors; FOXO1, forkhead box O1; FOXO3,

Download English Version:

<https://daneshyari.com/en/article/8266466>

Download Persian Version:

<https://daneshyari.com/article/8266466>

[Daneshyari.com](https://daneshyari.com)